CirculoGene utilizes next-generation sequencing (NGS) and polymerase chain reaction (PCR) methodologies to detect clinically significant tumor DNA and RNA alterations from blood samples, enhancing the accuracy of cancer diagnostics. This approach enables oncologists to personalize treatment plans and monitor patient responses, ultimately improving outcomes for cancer patients.
Funding
$22.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be time-consuming and may not always capture the full molecular profile of the tumor. This can lead to delays in treatment and potentially less effective personalized therapies. Additionally, monitoring treatment response can be challenging without frequent invasive procedures.
Solution
CirculoGene offers a comprehensive suite of blood-based liquid biopsy tests that detect clinically significant tumor DNA and RNA alterations, providing a non-invasive alternative or complement to traditional tissue biopsies. By utilizing next-generation sequencing (NGS) and polymerase chain reaction (PCR) methodologies, CirculoGene's tests, including TumorClear, ImmunoClear, and MSI Complete, enable oncologists to personalize treatment plans based on a patient's unique molecular fingerprint. The company's patented methodology increases the yield of cell-free DNA (cfDNA) and preserves fragile cell-free RNA (cfRNA), allowing for a more complete and accurate analysis of a patient's cancer. CirculoGene's approach facilitates faster time to treatment, provides insights for first-line treatment decisions, and allows for ongoing monitoring of treatment response, with the goal of improving patient outcomes and survival.
Target Audience
The primary target audience includes oncologists and other healthcare providers who require comprehensive and minimally invasive methods for cancer diagnostics, treatment planning, and monitoring of treatment response.
Features
- Patented methodology for increased yield of cfDNA and preservation of fragile cfRNA.
- Combined NGS and PCR methodologies for comprehensive DNA and RNA analysis.
- TumorClear: Identifies NCCN essential guideline and expert-based DNA markers.
- ImmunoClear: Offers plasma cfRNA PD-L1 detection for immunotherapy insights.
- MSI Complete: Utilizes advanced MSI technology for enhanced detection.
- LungLifeAI: AI-driven blood-based test for indeterminate pulmonary nodule assessment.
- Actionable reports highlighting significant findings and referenced FDA-approved treatment options.